Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Prognostic immunologic signatures in epithelial ovarian cancer

Oncogene volume 41, pages 1389–1396 (2022)Cite this article

Subjects

Abstract

Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharm. 2018;81:17–38.

    Article  CAS  Google Scholar 

  2. Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, et al. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget. 2017;8:12389–405.

    Article  PubMed  Google Scholar 

  3. Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012;13:1523–35.

    Article  CAS  PubMed  Google Scholar 

  4. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015–22.

    Article  CAS  PubMed  Google Scholar 

  5. James NE, Woodman M, DiSilvestro PA, Ribeiro JR. The perfect combination: enhancing patient response to PD-1-based therapies in epithelial ovarian cancer. Cancers. 2020;12:2050.

    Article  Google Scholar 

  6. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.

    Article  CAS  PubMed  Google Scholar 

  7. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393–402.

    Article  CAS  PubMed  Google Scholar 

  8. Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, et al. Immune gene expression and response to chemotherapy in advanced breast cancer. Br J Cancer. 2018;118:480–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wu Y, Xia L, Zhao P, Deng Y, Guo Q, Zhu J, et al. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. Aging (Albany, NY). 2020;12:11398–415.

    Article  CAS  Google Scholar 

  10. Honkala AT, Tailor D, Malhotra SV. Guanylate-binding protein 1: an emerging target in inflammation and cancer. Front Immunol. 2019;10:3139.

    Article  CAS  PubMed  Google Scholar 

  11. Harwood FC, Klein Geltink RI, O’Hara BP, Cardone M, Janke L, Finkelstein D, et al. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018;4:eaar3938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lu X, Ji C, Jiang L, Zhu Y, Zhou Y, Meng J, et al. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy. Cell Prolif. 2021;54:e12979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, et al. Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling. PeerJ 2020;8:e10414.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ding Q, Dong S, Wang R, Zhang K, Wang H, Zhou X, et al. A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer. Aging. 2020;12:4879–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Khadirnaikar S, Kumar P, Shukla SK. Development and validation of an immune prognostic signature for ovarian carcinoma. Cancer Rep. 2020;3:e1166.

    CAS  Google Scholar 

  16. Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei Y, et al. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine 2019;40:318–26.

    Article  PubMed  Google Scholar 

  17. Zhang L, Zhu P, Tong Y, Wang Y, Ma H, Xia X, et al. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma. Onco Targets Ther. 2019;12:7005–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yan S, Fang J, Chen Y, Xie Y, Zhang S, Zhu X, et al. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. BMC Cancer. 2020;20:1205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhang B, Nie X, Miao X, Wang S, Li J, Wang S. Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer. J Cell Mol Med. 2021;25:2918–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK. et al. RNA immune signatures from pan-cancer analysis are prognostic for high-grade serous ovarian cancer and other female cancers. Cancers.2020;12:620.

    Article  CAS  PubMed Central  Google Scholar 

  21. Talluri B, Amar K, Saul M, Shireen T, Konjufca V, Ma J. et al. COL2A1 is a novel biomarker of melanoma tumor repopulating cells. Biomedicines. 2020;8:360.

    Article  CAS  PubMed Central  Google Scholar 

  22. Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD. Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer. 2016;16:911.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Li H, Wu N, Liu Z-Y, Chen Y-C, Cheng Q, Wang J. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer. Sci Rep. 2021;11:7207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cao T, Shen H. Development of a multi-gene-based immune prognostic signature in ovarian Cancer. J Ovarian Res. 2021;14:20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ray M, Ruffalo MM, Bar-Joseph Z. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer. Genes Chromosomes Cancer. 2019;58:34–42.

    Article  CAS  PubMed  Google Scholar 

  26. Guo Q, Cheng Y, Liang T, He Y, Ren C, Sun L, et al. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression. Sci Rep. 2015;5:17683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Korsunsky I, Parameswaran J, Shapira I, Lovecchio J, Menzin A, Whyte J, et al. Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer. J Investig Med. 2017;65:1068–76.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci. 2019;20:4781.

    Article  PubMed Central  Google Scholar 

  29. Chang CC, Su KM, Lu KH, Lin CK, Wang PH, Li H-Y. et al. Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis. Int J Mol Sci. 2018;19:3311.

    Article  PubMed Central  Google Scholar 

  30. Liu J, Tan Z, He J, Jin T, Han Y, Hu L. et al. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. Biosci Rep. 2020;40:20201431.

    Article  Google Scholar 

  31. James NE, Miller K, LaFranzo N, Lips E, Woodman M, Ou J, et al. Immune modeling analysis reveals immunologic signatures associated with improved outcomes in high grade serous ovarian cancer. Front Oncol. 2021;11:622182.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Siamakpour-Reihani S, Cobb LP, Jiang C, Zhang D, Previs RA, Owzar K, et al. Differential expression of immune related genes in high-grade ovarian serous carcinoma. Gynecol Oncol. 2020;156:662–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mairinger F, Bankfalvi A, Schmid KW, Mairinger E, Mach P, Walter RF, et al. Digital immune-related gene expression signatures in high-grade serous ovarian carcinoma: developing prediction models for platinum response. Cancer Manag Res. 2019;11:9571–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rådestad E, Klynning C, Stikvoort A, Mogensen O, Nava S, Magalhaes I, et al. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. 2019;8:e1535730.

    Article  PubMed  Google Scholar 

  35. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(Mar):1459.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Vankerckhoven A, Baert T, Riva M, De Bruyn C, Thirion G, Vandenbrande K, et al. Type of chemotherapy has substantial effects on the immune system in ovarian cancer. Transl Oncol. 2021;14:101076.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Liu S, Imani S, Deng Y, Pathak JL, Wen Q, Chen Y, et al. Targeting IFN/STAT1 pathway as a promising strategy to overcome radioresistance. Onco Targets Ther. 2020;13:6037–50.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;112:1215–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hao D, Liu J, Chen M, Li J, Wang L, Li X, et al. Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity. Clin Cancer Res. 2018;24:3560–71.

    Article  CAS  PubMed  Google Scholar 

  40. Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, et al. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Med. 2021;10:3045–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier D-L, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52:582–93.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Brunekreeft KL, Paijens ST, Wouters MCA, Komdeur FL, Eggink FA, Lubbers JM, et al. Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology 2020;9:1760705.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28:651–7.

    Article  CAS  PubMed  Google Scholar 

  44. Böhm S, Montfort A, Pearce OMT, Topping J, Chakravarty P, Everitt GLA, et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res. 2016;22:3025–36.

    Article  PubMed  Google Scholar 

  45. Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang I-M, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J Immunother Cancer. 2019;7:325.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Chang L, Ni J, Zhu Y, Pang B, Graham P, Zhang H, et al. Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics. 2019;9:4130–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Mlynska A, Salciuniene G, Zilionyte K, Garberyte S, Strioga M, Intaite B, et al. Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration. Oncol Rep. 2019;41:1238–52.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Swim Across America and The Program in Women’s Oncology at Women and Infants Hospital of Rhode Island.

Author information

Authors and Affiliations

  1. Women and Infants Hospital, Department of Obstetrics and Gynecology, Program in Women’s Oncology, Providence, RI, USA

    Nicole E. James, Morgan Woodman & Jennifer R. Ribeiro

  2. Warren Alpert School of Medicine, Brown University, Providence, RI, USA

    Nicole E. James & Jennifer R. Ribeiro

Authors
  1. Nicole E. James
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan Woodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer R. Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NER and JRR conceptually developed this manuscript. NER and MW performed literature reviews. NER wrote the manuscript in its entirety, and JRR edited it.

Corresponding author

Correspondence to Jennifer R. Ribeiro.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

James, N.E., Woodman, M. & Ribeiro, J.R. Prognostic immunologic signatures in epithelial ovarian cancer. Oncogene 41, 1389–1396 (2022). https://doi.org/10.1038/s41388-022-02181-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-022-02181-5

This article is cited by

Search

Advanced search

Quick links